The US Novavax Covid-19 vaccine will be tested this year on 200 volunteers aged over 20.
Japanese pharmaceutical company Takeda announced that it has initiated in-country clinical trials of the new variant of Coronavirus (Covid-19) vaccine developed by the US biotech firm Novavax.
As announced by Takeda, the US developed Covid-19 vaccine Novavax will be tested this year to 200 volunteers over the age of 20 in the country.
Stating that it aims to manufacture the vaccine in the second half of this year, Takeda said it has the capacity to manufacture more than 250 million doses.
The firm is already conducting clinical trials of the US-based Moderna’s Covid-19 vaccine in Japan.
If the vaccine manufactured by Moderna receives approval from Japan, Takeda will import 50 million doses of Moderna vaccine and ensure domestic distribution.
A total of 310 million vaccines have been ordered
The government announced that a total of 310 million vaccines had been ordered from BioNTech-Pfizer, AstraZeneca and Moderna firms.
In the first half of this year, the vaccine supply for the country's total population is targeted.